Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (12)

2022

  1. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL

    Molecular Therapy, Vol. 30, Núm. 2, pp. 550-563

2021

  1. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 5, pp. 328-337.e1

2020

  1. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

    Blood Advances, Vol. 4, Núm. 10, pp. 2163-2171

  2. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia

    BMJ Open, Vol. 10, Núm. 1

2019

  1. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

    Leukemia, Vol. 33, Núm. 7, pp. 1557-1569

2016

  1. Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency

    Stem Cell Reports, Vol. 7, Núm. 4, pp. 602-618

  2. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

2012

  1. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

    Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819

2010

  1. Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

    Blood, Vol. 116, Núm. 8

2009

  1. The Chemokine Receptor CXCR4 and the Metalloproteinase MT1-MMP Are Mutually Required during Melanoma Metastasis to Lungs

    American Journal of Pathology, Vol. 174, Núm. 2, pp. 602-612